Last reviewed · How we verify
ANG3070
At a glance
| Generic name | ANG3070 |
|---|---|
| Sponsor | Angion Biomedica Corp |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study to Assess the Safety and Tolerability of ANG-3070 in Subjects With Idiopathic Pulmonary Fibrosis (PHASE1)
- Study of Safety and Efficacy of ANG-3070 in Chronic Kidney Disease (PHASE2)
- ANG-3070 in Healthy Adult Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ANG3070 CI brief — competitive landscape report
- ANG3070 updates RSS · CI watch RSS
- Angion Biomedica Corp portfolio CI